Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Gross Profit (2016 - 2025)

Guided Therapeutics' Gross Profit history spans 15 years, with the latest figure at $34000.0 for Q3 2025.

  • For Q3 2025, Gross Profit changed N/A year-over-year to $34000.0; the TTM value through Sep 2025 reached $111000.0, up 455.0%, while the annual FY2024 figure was $2000.0, 94.44% down from the prior year.
  • Gross Profit for Q3 2025 was $34000.0 at Guided Therapeutics, down from $79000.0 in the prior quarter.
  • Across five years, Gross Profit topped out at $79000.0 in Q2 2025 and bottomed at -$79000.0 in Q4 2022.
  • The 5-year median for Gross Profit is $4000.0 (2022), against an average of $6866.7.
  • The largest annual shift saw Gross Profit crashed 292.68% in 2022 before it surged 225.0% in 2023.
  • A 5-year view of Gross Profit shows it stood at $41000.0 in 2021, then plummeted by 292.68% to -$79000.0 in 2022, then skyrocketed by 120.25% to $16000.0 in 2023, then plummeted by 112.5% to -$2000.0 in 2024, then skyrocketed by 1800.0% to $34000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Gross Profit are $34000.0 (Q3 2025), $79000.0 (Q2 2025), and -$2000.0 (Q4 2024).